Molecular Partners (MOLN) Expected to Release Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) will likely be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.46) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:00 AM ET.

Molecular Partners (NASDAQ:MOLN) last announced its earnings results on Tuesday, August 25th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.01. On average, analysts expect Molecular Partners to post ($1.28) EPS for the current fiscal year and ($0.36) EPS for the next fiscal year.

Molecular Partners Price Performance

Shares of MOLN opened at $3.70 on Thursday. The company has a 50 day moving average of $4.11 and a 200-day moving average of $4.07. The stock has a market capitalization of $149.39 million, a P/E ratio of -2.16 and a beta of 1.11. Molecular Partners has a twelve month low of $3.52 and a twelve month high of $5.36.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MOLN. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a report on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland, and listed on Nasdaq under the symbol MOLN. The company develops targeted therapies using its proprietary DARPin platform, which is designed to create small, modular proteins that can bind selectively to disease-related targets and be engineered into multi-specific medicines.

Molecular Partners’ research and development activities have focused primarily on oncology and immuno-oncology, including treatments intended to engage or modulate the immune system and address complex biological targets.